Literature DB >> 15468194

Growth factor displayed on the surface of retroviral particles without manipulation of envelope proteins is biologically active and can enhance transduction.

Anil Chandrashekran1, Myrtle Y Gordon, David Darling, Farzin Farzaneh, Colin Casimir.   

Abstract

BACKGROUND: The therapeutic potential of retroviruses can be significantly enhanced by display of specific molecules on the retroviral surface. This has been conventionally achieved by the manipulation of retroviral envelope proteins. In this report we have tested whether the natural budding mechanism of the retrovirus could be exploited to incorporate a specific molecule into the retroviral surface.
METHODS: Retroviral packaging cells were engineered to express the membrane-bound form of human stem cell factor (mbSCF). Surface expression of mbSCF on retroviral packaging cells was confirmed by immunofluorescence and flow cytometry. Incorporation of mbSCF into retroviral particles was demonstrated by virus-binding assay and immunomagnetic capture of virus using antibody to SCF. Retroviral supernatants were tested for activity of the incorporated cytokine by proliferation assays on factor-dependent cells. Amphotropic retrovirus displaying surface mbSCF was used to transduce SCF receptor-positive haematopoietic cells.
RESULTS: Retroviruses incorporating surface SCF showed increased levels of binding to cells (MO7e) expressing the SCF receptor, c-kit. mbSCF displayed on the viral surface retained levels of biological activity comparable with those of soluble recombinant growth factor. Transduction of c-kit-positive target cells with viruses displaying mbSCF showed enhanced levels of transduction in comparison with unmodified viruses.
CONCLUSIONS: Expression of the membrane-bound form of human stem cell factor (mbSCF) on the surface of retroviral packaging cells allows its efficient incorporation into retrovirus particles in a biologically active form, opening up the possibility for the use of retroviral display in many therapeutic areas, such as in gene therapy, drug delivery and in the development of novel vaccines.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15468194     DOI: 10.1002/jgm.625

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  4 in total

1.  Conjugation of lentivirus to paramagnetic particles via nonviral proteins allows efficient concentration and infection of primary acute myeloid leukemia cells.

Authors:  Lucas Chan; Darren Nesbeth; Taylor Mackey; Joanna Galea-Lauri; Joop Gäken; Francisco Martin; Mary Collins; Ghulam Mufti; Farzin Farzaneh; David Darling
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

2.  Changing viral tropism using immunoliposomes alters the stability of gene expression: implications for viral vector design.

Authors:  Peng H Tan; Shao-An Xue; Bin Wei; Angelika Holler; Ralf-Holger Voss; Andrew J T George
Journal:  Mol Med       Date:  2007 Mar-Apr       Impact factor: 6.354

3.  Cell-specific targeting of lentiviral vectors mediated by fusion proteins derived from Sindbis virus, vesicular stomatitis virus, or avian sarcoma/leukosis virus.

Authors:  Xian-Yang Zhang; Robert H Kutner; Agnieszka Bialkowska; Michael P Marino; William B Klimstra; Jakob Reiser
Journal:  Retrovirology       Date:  2010-01-25       Impact factor: 4.602

4.  Lentiviral vector transduction of spermatozoa as a tool for the study of early development.

Authors:  Anil Chandrashekran; Ihsan Isa; Jayesh Dudhia; Adrian J Thrasher; Nicholas Dibb; Colin Casimir; Carol Readhead; Robert Winston
Journal:  FEBS Open Bio       Date:  2014-03-03       Impact factor: 2.693

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.